Photo for illustration (Source: moh.gov.vn)

Seventeen of them were given a 25mcg dose of Nanocovax, Việt Nam’s first candidate vaccine against SARS-CoV-2 to reach the human trial stage.

Three others received a 50mcg dose of Nanocovax. They were given the first shot on December 26, 2020.

A total of 60 volunteers, aged 18-50, were selected for the first phase of Nanocovax’s clinical trials. They are divided into three groups for receiving three doses of 25 mcg, 50 mcg and 75 mcg, respectively. The vaccination consists of two injections 28 days apart.

Among 20 candidates of the 25mcg dose group, three were injected with the second dose on January 14. All of them are now in stable condition.

Among them, three people, who had been injected a dose on December 26, 2020, were given a dose of 50mcg and the remainders got a dose of 25 mcg. All of the volunteers are now in stable conditions.

The third stage, scheduled for August, will see trials on 10,000 - 30,000.

If successful, Vietnam will begin mass production of the COVID-19 vaccine in early 2022./.

BTA